Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $650.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective boosted by Wells Fargo & Company from $550.00 to $650.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the pharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 20.04% from the company’s current price.

Several other equities research analysts have also commented on VRTX. Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group set a $653.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 1st. Truist Financial upped their target price on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Morgan Stanley began coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They set an “overweight” rating and a $665.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on Vertex Pharmaceuticals in a research note on Friday, September 11th. They issued an “overweight” rating and a $560.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $587.63.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded down $11.65 on Tuesday, hitting $541.50. 531,346 shares of the company’s stock were exchanged, compared to its average volume of 1,385,165. The firm’s 50-day moving average price is $523.32 and its two-hundred day moving average price is $479.96. Vertex Pharmaceuticals has a fifty-two week low of $403.16 and a fifty-two week high of $568.67. The firm has a market cap of $137.44 billion, a price-to-earnings ratio of 31.49, a P/E/G ratio of 2.54 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period last year, the company posted $4.80 earnings per share. On average, research analysts predict that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Institutional Trading of Vertex Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Summit Global Investments bought a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $3,568,000. Calamos Advisors LLC grew its stake in Vertex Pharmaceuticals by 77.1% during the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after buying an additional 33,917 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth about $13,823,000. UNIVEST FINANCIAL Corp acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $4,495,000. Finally, Meeder Advisory Services Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $3,187,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the company’s cystic fibrosis franchise and the ramp-up of newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.2 billion-$13.3 billion and highlighted continued pipeline advancement and the completed acquisition of Crinetics Pharmaceuticals. Analysts also became more constructive: Cantor Fitzgerald raised its price target to $619 from $595 and maintained an “overweight” rating. Cantor Fitzgerald Vertex rating
• Neutral Sentiment: Stifel Nicolaus increased its price target to $563 from $500 but retained a “hold” rating, signaling that much of the expected upside may already be reflected in the shares. Stifel Nicolaus Vertex rating
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Heavy investment in new product launches and the Crinetics transaction limited profit growth despite higher sales. Vertex spends cash flow on new launches
• Negative Sentiment: The revenue outlook is only modestly above the previous forecast and roughly in line with consensus, which may disappoint investors looking for a larger guidance increase. The mixed earnings report has produced a volatile reaction, with the earnings miss and light outlook offsetting the revenue beat.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.